1775. Estimates of parainfluenza virus-associated hospitalizations and cost among children aged less than 5 years in the United States, 1998 2010
Session: Poster Abstract Session: Viral Infections; Pathogenesis and Epidemiology
Saturday, October 5, 2013
Room: The Moscone Center: Poster Hall C
  • Poster 8x4 09252013 REVISED.pdf (379.8 kB)
  • Background:

    Parainfluenza viruses (PIV) represent the second leading cause of hospitalization for respiratory illness in young children in the US. The diagnoses most commonly associated with PIV hospitalizations are bronchiolitis, croup, and pneumonia. We estimate the annual number of PIV-related hospitalizations for these diagnoses in the US and their costs.


    To estimate the number of PIV-associated hospitalizations occurring annually in US children aged <5 years, the 1998 – 2010 Healthcare Cost and Utilization Project Nationwide Inpatient Sample estimates of bronchiolitis, croup, and pneumonia hospitalizations were multiplied by the proportions of PIV-associated hospitalizations associated with those diagnoses as observed in the New Vaccine Surveillance Network from 2001 to 2004.  From these numbers, PIV-associated hospitalization rates and associated charges were calculated.


    The average annual estimates of PIV-associated bronchiolitis, croup, and pneumonia hospitalizations (rates per 1000 children) among patients aged <5 years in the United States were 5,779 (0.3), 8,483 (0.4), and 8,311 (0.4), respectively.  The combined PIV hospitalization rate was highest among children aged <1 year (2.2).  By age group and condition, the PIV-associated hospitalization rates were highest among children aged <6 months for bronchiolitis and pneumonia combined (1.8) and children aged 1-2 years for croup (0.7). Annual charges for PIV-associated bronchiolitis, croup, and pneumonia hospitalizations were estimated to total 56 million USD, 46 million USD, and 115 million USD, respectively.


    One in 455 infants is estimated to be hospitalized with PIV infection annually. PIV remains among the leading causes of lower respiratory illness and hospitalization in infants and contributes substantially to healthcare expenditures. These results highlight the need for continued PIV vaccine development.

    Glen Abedi, MPH, Mila Prill, Mary Wikswo, Gayle E. Langley, MD, MPH, Aaron T. Curns, MPH and Eileen Schneider, MD, MPH, Centers for Disease Control and Prevention, Atlanta, GA


    G. Abedi, None

    M. Prill, None

    M. Wikswo, None

    G. E. Langley, None

    A. T. Curns, None

    E. Schneider, None

    Findings in the abstracts are embargoed until 12:01 a.m. PST, Oct. 2nd with the exception of research findings presented at the IDWeek press conferences.